Nonvirally modified autologous primary hepatocytes correct diabetes and prevent target organ injury in a large preclinical model.
<h4>Background</h4>Current gene- and cell-based therapies have significant limitations which impede widespread clinical application. Taking diabetes mellitus as a paradigm, we have sought to overcome these limitations by ex vivo electrotransfer of a nonviral insulin expression vector int...
Guardado en:
Autores principales: | Nelson K F Chen, Jen San Wong, Irene H C Kee, Siang Hui Lai, Choon Hua Thng, Wai Har Ng, Robert T H Ng, Soo Yong Tan, Shu Yen Lee, Mark E H Tan, Jaichandran Sivalingam, Pierce K H Chow, Oi Lian Kon |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d6d641e5934441eda05c41c85f05a2af |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeted nonviral gene therapy in prostate cancer
por: Altwaijry N, et al.
Publicado: (2018) -
Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival
por: Siew Hong Leong, et al.
Publicado: (2017) -
Research progress on siRNA delivery with nonviral carriers
por: Gao Y, et al.
Publicado: (2011) -
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tetsu Tomonari, et al.
Publicado: (2021) -
Polyethylenimine600-β-cyclodextrin: a promising nanopolymer for nonviral gene delivery of primary mesenchymal stem cells
por: Tong H, et al.
Publicado: (2013)